JP2020521448A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521448A5 JP2020521448A5 JP2019564793A JP2019564793A JP2020521448A5 JP 2020521448 A5 JP2020521448 A5 JP 2020521448A5 JP 2019564793 A JP2019564793 A JP 2019564793A JP 2019564793 A JP2019564793 A JP 2019564793A JP 2020521448 A5 JP2020521448 A5 JP 2020521448A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 161
- 239000000427 antigen Substances 0.000 claims description 93
- 102000036639 antigens Human genes 0.000 claims description 93
- 108091007433 antigens Proteins 0.000 claims description 93
- 102000004169 proteins and genes Human genes 0.000 claims description 74
- 108090000623 proteins and genes Proteins 0.000 claims description 74
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 15
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 15
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 9
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 6
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 6
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000008968 osteosarcoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 208000037965 uterine sarcoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 239000001608 potassium adipate Substances 0.000 claims description 2
- 239000001601 sodium adipate Substances 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 96
- 239000000203 mixture Substances 0.000 claims 10
- 238000009472 formulation Methods 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510135P | 2017-05-23 | 2017-05-23 | |
| US62/510,135 | 2017-05-23 | ||
| US201762549200P | 2017-08-23 | 2017-08-23 | |
| US62/549,200 | 2017-08-23 | ||
| PCT/US2018/033952 WO2018217799A1 (en) | 2017-05-23 | 2018-05-22 | A protein binding nkg2d, cd16 and ror1 or ror2 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020521448A JP2020521448A (ja) | 2020-07-27 |
| JP2020521448A5 true JP2020521448A5 (enExample) | 2021-07-26 |
Family
ID=64397001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564793A Pending JP2020521448A (ja) | 2017-05-23 | 2018-05-22 | Ｎｋｇ２ｄ、ｃｄ１６、およびｒｏｒ１またはｒｏｒ２に結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200157174A1 (enExample) |
| EP (1) | EP3630183A4 (enExample) |
| JP (1) | JP2020521448A (enExample) |
| KR (1) | KR20200010428A (enExample) |
| CN (1) | CN111263643A (enExample) |
| AU (1) | AU2018271872A1 (enExample) |
| BR (1) | BR112019024654A2 (enExample) |
| CA (1) | CA3064743A1 (enExample) |
| IL (1) | IL270794A (enExample) |
| MX (1) | MX2019013998A (enExample) |
| WO (1) | WO2018217799A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4491234A3 (en) | 2017-02-08 | 2025-04-09 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| BR112019017197A2 (pt) | 2017-02-20 | 2020-04-14 | Dragonfly Therapeutics, Inc. | proteínas que se ligam a her2, nkg2d e cd16 |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201721802D0 (en) * | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
| AU2019218125B2 (en) | 2018-02-08 | 2025-03-13 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| KR20250112921A (ko) | 2018-08-08 | 2025-07-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN111378039B (zh) * | 2018-12-29 | 2021-08-24 | 深圳大学 | 治疗恶性肿瘤的抗体及其应用 |
| CN111378040B (zh) * | 2018-12-29 | 2021-08-10 | 深圳大学 | 检测多种恶性肿瘤细胞的抗体及其应用 |
| EP4146271A4 (en) | 2020-05-06 | 2024-09-04 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A |
| CA3172530A1 (en) | 2021-02-25 | 2022-09-01 | Spencer PARK | Ror1 targeting chimeric antigen receptor |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| EP4423145A1 (en) | 2021-10-28 | 2024-09-04 | Lyell Immunopharma, Inc. | Methods for culturing cells expressing ror1-binding protein |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2418223A3 (en) * | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| JP5591712B2 (ja) * | 2007-12-14 | 2014-09-17 | ノボ・ノルデイスク・エー／エス | ヒトｎｋｇ２ｄに対する抗体とその使用 |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| WO2011159847A2 (en) * | 2010-06-15 | 2011-12-22 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof |
| EP2714738B1 (en) * | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| TWI742423B (zh) * | 2014-05-29 | 2021-10-11 | 美商宏觀基因股份有限公司 | 特異性結合多種癌症抗原的三特異性結合分子和其使用方法 |
| US20180318417A1 (en) * | 2015-01-14 | 2018-11-08 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| AR100680A1 (es) * | 2015-01-26 | 2016-10-26 | Macrogenics Inc | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos |
| WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| EP3297671A4 (en) * | 2015-05-18 | 2019-02-06 | Eureka Therapeutics, Inc. | ANTI-ROR1 ANTIBODY |
| AU2016284866B2 (en) * | 2015-06-23 | 2022-09-29 | Innate Pharma | Multispecific antigen binding proteins |
| EP3374389A1 (en) * | 2015-11-13 | 2018-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
| UY37127A (es) * | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
-
2018
- 2018-05-22 CA CA3064743A patent/CA3064743A1/en active Pending
- 2018-05-22 EP EP18806428.1A patent/EP3630183A4/en not_active Withdrawn
- 2018-05-22 MX MX2019013998A patent/MX2019013998A/es unknown
- 2018-05-22 BR BR112019024654A patent/BR112019024654A2/pt not_active IP Right Cessation
- 2018-05-22 WO PCT/US2018/033952 patent/WO2018217799A1/en not_active Ceased
- 2018-05-22 AU AU2018271872A patent/AU2018271872A1/en not_active Abandoned
- 2018-05-22 KR KR1020197037751A patent/KR20200010428A/ko not_active Ceased
- 2018-05-22 CN CN201880051762.0A patent/CN111263643A/zh active Pending
- 2018-05-22 US US16/615,203 patent/US20200157174A1/en not_active Abandoned
- 2018-05-22 JP JP2019564793A patent/JP2020521448A/ja active Pending
-
2019
- 2019-11-20 IL IL270794A patent/IL270794A/en unknown